The Clinical Research Of The Role And Optimal Inventation Timing Of Chest Radiotherapy For ? Period Oligometastatic NSCLC

Objective:This study was designed to clarify the significance of thoracic radiotherapy in the treatment of stage ? oligometastasis NSCLC,to explore the optimal timing of chest radiotherapy,and to analyze the prognostic factors to improve the local control rate of ? patients,thereby extending the survival time and improve the prognosis.Methods:Collected 402 cases of pathological diagnostic oligometastatic NSCLC patients from January 2008 to December 2014,including 96 of pure chemotherapy group,91 of early radiotherapy intervention group,109 of medium radiotherapy intervention group,106 of late radiotherapy intervention group.Total radiation dose <60Gy are 163 cases,and 143 patients ?60Gy.The whole group patients adopted platinum-based chemotherapy,per cycle for 21-28 days,and all patients have completed six cycles of chemotherapy.Results:The median survival time for 4 groups patients were 8.70 months,15.90 months,16.17 months and 16.17 months,respectively,?2= 40.42,P< 0.001,1 year survival rate were 47.6%,73.4%,72.1% and 47.6% respectively,and 2 year survival rate were 5.2%,35.3%,34.7% and 35.3%,respectively.Patients with radiotherapy have relatively better survival time than pure chemotherapy group,early and medium groups better than late group as well.The median survival time of total radiation dose <60Gy group and ?60Gygroup were 12.50 months and 18.22 months respectively,with 1 year survival rate 56.3%and 72.2% and 2 year survival rate 23.8% and 51.3%,?2= 5.75,P= 0.02,high dose group has longer survival time than low dose group.Conclusion:For ? phase oligometastatic NSCLC patients,early high doses radiation to chest tumor can improve local control rate and prolong the survival time...